At the completion of this educational session, participants should be able to:
- Review the completed and ongoing clinical trials that use antiretroviral agents for HIV prevention.
- Outline potential reasons for the current discrepant clinical trial results.
- Discuss agents and modes of delivery currently in the HIV prevention pipeline.
- Review future strategies and optimal clinical trial designs for HIV chemoprophylaxis.
Angela Kashuba has been on faculty at the University of North Carolina at Chapel Hill since 1997, and is currently an Associate Professor in the UNC School of Pharmacy, and directs both the UNC Center for AIDS Research Clinical Pharmacology and Analytical Chemistry Core and the Pharmacology Core for the UNC Delaney Collaboratory. She is a Diplomate of the American Board of Clinical Pharmacology and was the 2009 recipient of the Leon I. Goldberg Young Investigator Award from the American Society of Clinical
Pharmacology and Therapeutics. Dr. Kashuba has authored over 110 publications and has received ~$12 million in research funding. Her research is focused on utilizing antiretrovirals to prevent HIV transmission, and she is currently involved in evaluating drug concentration-effect relationships in CAPRISA 004 and FEMPrEP.
To obtain CME credit for this and other PRN programs, please visit the PRN Video Channel
at the Clinical Education Initiative (CEI) web site. PRN and the Medical Society of the State of New York (MSSNY) jointly sponsor PRN enduring materials for CME, and provide them at no cost to the AIDS Institute of the New York State Department of Health (NYSDOH) for broadcast through the CEI. We thank the NYSDOH for making our CME programs available to a wider audience, and hope you will also browse the many other educational opportunities offered by the CEI.